The world's pharmaceutical giant is exposed to huge bribes in China

After GlaxoSmithKline, Sanofi and Novartis, foreign pharmaceutical companies reappear "former employees" counter attack reports Yesterday, the former senior manager of Lilly, the world's pharmaceutical giant, revealed that almost all the drugs used by the company in the field of endocrinology are suspected of paying bribes to doctors, and two of its insulin products pay at least 30 million yuan a year Lilly said it had investigated the company in 2012, but found no strong evidence It is revealed that at least 30 million bribes are paid each year The products exposed this time almost cover all the drugs used in the endocrine field of Lilly Among them, the products such as youbile, youbilin, youbile classic and youban II are the insulin drugs strongly promoted by the company in recent years According to media reports, Wang Wei (pseudonym), a former senior manager of Lilly, revealed that unlike the amount of prescriptions for ordinary drugs linked to the amount of bribes, Lilly's rebate for insulin products is to compensate doctors according to the number of newly developed patients because insulin needs to be used for a long time The specific approach is that every time a new patient uses ubilin product, the doctor will fill in a "return card" to record his personal information and medication details The task of the medical representative is to collect the card regularly and pay the corresponding remuneration to the doctor according to the number of card returned by the new patient According to people familiar with the matter, the return points of drug agents nationwide range from 100 to 300 yuan per patient According to Wang Wei's statement, Lilai company's only two major products, youbilin pen classic and youban II, are nationwide, with a bribe amount of at least 30 million yuan a year In addition, Wang Wei said Lilly would also bribe doctors by falsely increasing meetings and paying high lecture fees Across the country, in 2011, Lilly spent 22 million yuan on lectures alone Yesterday, Lilly said that in 2012, the company did receive a very similar report from a former sales manager of Lilly in the region mentioned in the report At that time, the company made a thorough investigation of the rebate issues reflected by the parties The survey was thorough, including employee interviews, email inspections and cost audits "Although we did not find any evidence to prove the violations reported by the parties in the investigation in 2012, the company attaches great importance to this and we are still in-depth investigation." In addition, Lilly also revealed that the company has a comprehensive compliance and internal control system, which requires that the labor income of the lecturer be consistent with the fair value of the market, and conduct due diligence before employing doctors to provide services for Lilly At the same time, it will conduct compliance spot check, internal control audit and monthly payment bill spot check In the interview, many medical representatives said that Lilly will make ambitious performance growth plans every year Due to the limited patients in many fields, the monthly sales assessment pressure is very big, and it is impossible to complete the task with a fully compliant sales method According to the information provided by the informant, Lilly has a strict reward and punishment mechanism for the number of returned cards A medical representative focuses on 10-15 hospitals In Anhui Province, each medical representative requires to develop 300-400 patients a month If not, they will be gradually eliminated from the team Introduction: Lilly is a global R & D-based pharmaceutical company, headquartered in Indianapolis, Indiana, USA, with a history of 130 years In China, it has a wholly owned enterprise, 30 offices and more than 3000 employees.